Multiparameter Flow Cytometry to Detect Hematogones and to Assess B-Lymphocyte Clonality in Bone Marrow Samples from Patients with Non-Hodgkin Lymphomas

Carulli, Giovanni; Ottaviano,; Guerri,; Giuntini, Stefano; Sammuri, Paola; Em, Ciancia; Azzarà, Antonio

doi:10.4081/hr.2014.5381

Cited by 5 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), and IHC with a greater proportion of cells expressing mature markers like CD19, CD20 when compared with immature markers (CD34, TdT) indicated hematogones. Similar findings were observed by Carulli et al and Rimsza et al [ 22 , 23 ].…”

Section: Discussionsupporting

confidence: 92%

Post-chemotherapy Changes in Bone Marrow in Acute Leukemia With Emphasis on Detection of Residual Disease by Immunohistochemistry

Ayyanar¹,

Kar²,

Dubashi³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Post-chemotherapy Changes in Bone Marrow in Acute Leukemia With Emphasis on Detection of Residual Disease by Immunohistochemistry

Ayyanar¹,

Kar²,

Dubashi³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…In MFC, FL B cells express the pan‐B antigens CD19, CD20, and CD22, with CD19 often dim. They usually lack CD5 expression but are characterized by the re‐expression of CD10, a marker lost after the hematogone progenitor stage . Combined with the presence of morphologically characteristic small cleaved centrocytes, CD10 expression (Figure A) is then very evocative of FL.…”

Section: Cd5‐negative B‐lpdsmentioning

confidence: 99%

Flow cytometry in the diagnosis of mature B‐cell lymphoproliferative disorders

Debord

Wuillème

Eveillard

et al. 2020

Int J Lab Hematology

View full text Add to dashboard Cite

B-lineage lymphoproliferative disorders (LPD) are rather frequent diseases, associated with specific clinical or biological features but also sometimes of fortuitous discovery. Multiparameter flow cytometry plays a major role for a rapid diagnostic indication, on peripheral blood or bone marrow samples in most instances, guiding complementary analyses and allowing for the proper therapeutic management of patients. After describing the important pre-analytical precautions required for an adequate assessment, the immunophenotypic features of small-cell and large-cell lymphomas are described in this review. The ubiquitous expression of CD19 is a first mandatory gating step. A possible clonal proliferation is then suspected by the demonstration of surface immunoglobulin light chain restriction. The aberrant presence of CD5 allows to segregate chronic lymphocytic leukemia and mantle cell lymphoma in most cases. Other LPD exhibit specific immunophenotypic features. A table of useful markers and a decision tree are provided. Of note, immunophenotypic data should as much as possible be interpreted in an integrated manner, involving the patient's clinical and other biological features, and be completed by further chromosomal and/or molecular investigations. K E Y W O R D S B-cell lymphoma, B-cell lymphoproliferative disorders, flow cytometry, immunophenotype, Matutes score

show abstract

“…In all cases, myeloaspirate samples were subjected to MFC analysis and HGs were detected and enumerated using a 7-fluorescence method [21], which is able to identify the three main HG subsets and mature, naïve B-lymphocytes in a single step. In addition, immunoglobulin (IgG, IgA, and IgM) levels were evaluated at diagnosis, after chemo-immunotherapy termination and during follow-up, in an attempt to correlate such parameters with the impact of therapy on B-lymphocyte ontogeny.…”

Section: Introductionmentioning

confidence: 99%

Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study

et al. 2015

Self Cite

View full text Add to dashboard Cite

Treatment with rituximab, either alone or in combination with antiblastic drugs, causes significant depletion of circulating B-lymphocytes and modifications of B cell maturation in the bone marrow. In the present study, we analyzed the kinetics of hematogones in bone marrow samples from 55 patients suffering from non-Hodgkin lymphomas and treated with rituximab-containing regimens. Maturation arrest at the level of stage 2 hematogones, along with complete depletion of naïve, mature B-lymphocytes, was observed as short-term effects (2 months after completion of chemo-immunotherapy). Further bone marrow samples, obtained 12 months after the last rituximab infusion in 21 patients undergoing long-term follow-up and treated with rituximab maintenance therapy, showed complete normalization of B-lymphocyte ontogeny. Hypogammaglobulinemia developed in 26 patients, and was still observed in nine of the 21 patients undergoing long-term follow-up. Our study provides novel data on hematogone kinetics in the setting of patients with non-Hodgkin lymphomas treated with chemo-immunotherapy containing rituximab and with rituximab maintenance. Our observations show that hypogammaglobulinemia can persist in a significant percentage of patients, despite complete recovery of B-lymphocyte ontogeny.

show abstract

Multiparameter Flow Cytometry to Detect Hematogones and to Assess B-Lymphocyte Clonality in Bone Marrow Samples from Patients with Non-Hodgkin Lymphomas

Cited by 5 publications

References 31 publications

Post-chemotherapy Changes in Bone Marrow in Acute Leukemia With Emphasis on Detection of Residual Disease by Immunohistochemistry

Post-chemotherapy Changes in Bone Marrow in Acute Leukemia With Emphasis on Detection of Residual Disease by Immunohistochemistry

Flow cytometry in the diagnosis of mature B‐cell lymphoproliferative disorders

Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study

Contact Info

Product

Resources

About